Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma
dc.contributor.author | Bhandari, Manish S. | en_US |
dc.contributor.author | Pienta, Kenneth J. | en_US |
dc.contributor.author | Fardig, Judith | en_US |
dc.contributor.author | Olson, Karin B. | en_US |
dc.contributor.author | Smith, David C. | en_US |
dc.date.accessioned | 2007-01-17T15:54:13Z | |
dc.date.available | 2007-01-17T15:54:13Z | |
dc.date.issued | 2006 | en_US |
dc.identifier.citation | Bhandari, Manish S.; Pienta, Kenneth J.; Fardig, Judith; Olson, Karin; Smith, David C. (2006)."Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma." Cancer 9999(9999): NA-NA. <http://hdl.handle.net/2027.42/49293> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/49293 | |
dc.description.abstract | BACKGROUND The current study evaluated the efficacy of oral uracil/tegafur (UFT) and leucovorin (LV) in patients with hormone-refractory metastatic prostrate carcinoma. METHODS Twenty-eight patients with hormone-refractory metastatic carcinoma of the prostate who had undergone antiandrogen withdrawal and no more than 1 prior chemotherapy treatment were enrolled on a single-institution Phase II trial. Patients were treated with oral UFT at a dose of 300 mg/m 2 /d and oral LV at a dose of 90 mg/day for 28 days followed by 7 days off therapy on a 35-day cycle regimen. RESULTS Twenty-six patients were evaluable for response and toxicity. There was no response by objective criteria in 9 patients with measurable disease. Four responses by prostate-specific antigen (PSA) criteria (i.e., PSA decrease by > 50%) were noted (15%) lasting a mean of 20.5 weeks. Therapy was generally well tolerated, with 2 patients developing Grade 4 toxicity (1 patient each with diarrhea and hand-foot syndrome) and 4 patients having significant Grade 3 toxicity (anemia, hyperbilirubinemia, and vomiting) (Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria). Six patients had stable disease by clinical, laboratory, and radiologic criteria for an average of 5 cycles of treatment (25 wks). CONCLUSIONS Although UFT and LV are generally well tolerated in the setting of hormone-refractory metastatic prostate carcinoma, the combination has a low level of activity. Its toxicity and activity is similar to that observed when intravenous 5-fluorouracil or capecitabine are given alone. It may be an option for further investigations in combination regimens. Cancer 2006. © 2006 American Cancer Society. | en_US |
dc.format.extent | 180449 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan ; University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 615-2719 ; Division of Hematology/Oncology, Department of Internal Medicine, 7302 CCGC 0946, University of Michigan, 1500 E. Medical Center Dr., Ann Arbor, MI 48109 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/49293/1/20436_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.21815 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.